For 2013 Avivagen is committed to executing a three-stage strategy for commercialization of the OxC-beta technology, targeting three major global markets:
-Companion animal and pet supplements for dogs, cats, horses and ornamental fish;
-A natural feed supplement used in livestock production to increase productivity through enhanced health and safety as an alternative to the current practice of using low dose antibiotics; and
-Human health applications based upon enhancement of immune function and decreased inflammation.